ECE2014 Poster Presentations Diabetes complications (59 abstracts)
1Department of Pathophysiology, Nicolaus Copernicus University in Torun, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland; 2Department of Endocrinology and Diabetology, Nicolaus Copernicus University in Torun, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland.
Introduction: Abnormal angiogenesis may contribute to impaired wound healing and the consequence of them is non-healing diabetic ulcers development. Therefore, the aim of the study was to evaluate the number of circulating EPCs, plasma levels of VEGF-A, sVEGF-R2 and FGF-2 in diabetic patients.
Materials and methods: Totally, 75 subjects were enrolled: 45 patients with type 2 diabetes (mean age 67.1 years) and 30 healthy volunteers (mean age 63.3 years). Patients were divided into two groups: 23 with DF (diabetic foot) and 22 without DF. VEGF-A, sVEGF-R2 and FGF-2 plasma concentrations were measured by ELISA. The number of EPCs was determined by flow cytometry.
Results: The results were presented in the table below.
Parameter | Patients with DF Me(Q1;Q3) I n=23 | Patients without DF Me(Q1;Q3) II n=22 | The control group Me(Q1;Q3) III n=30 | P value |
VEGF-A (pg/ml) | 36.0 (13.74;73.95) | 79.16 (29.56;131.55) | 15.06 (7.98;27.84) | I vs II P=0.04 |
I vs III P=0.01 | ||||
II vs III P=0.0002 | ||||
sVEGF-R2 (pg/ml) | 8930.5 (8360.0;10 356.0) | 10 099 (8765.2;10 841.5) | 10 738.75 (9670.5;11 766.0) | I vs II P=0.2 |
I vs III P=0.007 | ||||
II vs III P=0.07 | ||||
EPCs/μl | 0.41 (0.2;1.22) | 0.31 (0.1;1.53) | 0.41 (0.2;0.92) | I vs II P=0.0581 |
I vs III P=0.7 | ||||
II vs III P=0.6 | ||||
FGF-2 (pg/ml) | 6.39 (5.54;8.42) | 4.97 (4.45;6.02) | 4.92 (4.6;5.44) | I vs II P=0.0002 |
I vs III P=0.000003 | ||||
II vs III P=0.8 |
A significant negative correlation between EPCs and diabetes duration was observed (P=0.03, r=−0.43). Conclusions: The study demonstrated that diabetic patients with DF showed decreased VEGF-A and increased FGF-2 levels compared to the patients without DF. It might be associated with impaired angiogenic response.